These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1796300)

  • 1. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer.
    Jänicke F; Schmitt M; Graeff H
    Semin Thromb Hemost; 1991 Jul; 17(3):303-12. PubMed ID: 1796300
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
    Kim SJ; Shiba E; Kobayashi T; Yayoi E; Furukawa J; Takatsuka Y; Shin E; Koyama H; Inaji H; Takai S
    Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognostic value of urokinase-type plasminogen activator and 2 inhibitors PAI-1 and PAI-2 in breast cancer].
    Bouchet C; Spyratos F; Martin PM; Hacène K; Gentile A; Oglobine J
    Bull Cancer; 1994 Sep; 81(9):770-9. PubMed ID: 7703566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Detection of tumor markers in uterine cancer (plasminogen activators, plasminogen activator inhibitors) using fibrin autography].
    Itoh Y; Nozaki S; Sawaguchi K; Masuda T; Yabushita H; Noguchi M; Miyata N; Nakanishi M
    Nihon Sanka Fujinka Gakkai Zasshi; 1992 Oct; 44(10):1277-8. PubMed ID: 1431441
    [No Abstract]   [Full Text] [Related]  

  • 5. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
    Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
    Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasminogen activator system in oral squamous cell carcinoma.
    Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
    Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
    De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN
    J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma.
    Gandolfo GM; Conti L; Vercillo M
    Anticancer Res; 1996; 16(4B):2155-9. PubMed ID: 8694536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.
    Schmitt M; Jänicke F; Graeff H
    Blood Coagul Fibrinolysis; 1990 Dec; 1(6):695-702. PubMed ID: 2133250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
    Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
    Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue urokinase-type plasminogen activator receptor levels in breast cancer.
    Gong SJ; Rha SY; Chung HC; Yoo NC; Roh JK; Yang WI; Lee KS; Min JS; Kim BS; Chung HC
    Int J Mol Med; 2000 Sep; 6(3):301-5. PubMed ID: 10934293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasminogen activator in human breast cancer cytosols: revisited after five years.
    Ng R; Sutherland DJ; Szalai JP; Kellen JA
    In Vivo; 1991; 5(4):313-6. PubMed ID: 1810415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High tPA-expression in primary melanoma of the limb correlates with good prognosis.
    Ferrier CM; Suciu S; van Geloof WL; Straatman H; Eggermont AM; Koops HS; Kroon BB; Lejeune FJ; Kleeberg UR; van Muijen GN; Ruiter DJ
    Br J Cancer; 2000 Nov; 83(10):1351-9. PubMed ID: 11044361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
    Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Kolk A; Pautke C; Horch HH
    J Craniomaxillofac Surg; 2005 Jun; 33(3):191-6. PubMed ID: 15878520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Breast cancer: prognostic value of a dissemination index based on 4 components of the urokinase-type plasminogen activator system].
    Bouchet C; Hacène K; Martin PM; Becette V; Tubiana-Hulin M; Lasry S; Oglobine J; Spyratos F
    Pathol Biol (Paris); 2000 Nov; 48(9):825-31. PubMed ID: 11141918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines.
    Quax PH; van Leeuwen RT; Verspaget HW; Verheijen JH
    Cancer Res; 1990 Mar; 50(5):1488-94. PubMed ID: 2105839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urokinase-type plasminogen activator in human aqueous humor.
    Bernatchez SF; Tabatabay C; Belin D
    Invest Ophthalmol Vis Sci; 1992 Aug; 33(9):2687-92. PubMed ID: 1639615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
    Meijer-van Gelder ME; Look MP; Peters HA; Schmitt M; Brünner N; Harbeck N; Klijn JG; Foekens JA
    Cancer Res; 2004 Jul; 64(13):4563-8. PubMed ID: 15231667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue-type plasminogen activator, a new prognostic marker in breast cancer.
    Duffy MJ; O'Grady P; Devaney D; O'Siorain L; Fennelly JJ; Lijnen HR
    Cancer Res; 1988 Mar; 48(5):1348-9. PubMed ID: 3124957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.
    Foekens JA; Schmitt M; van Putten WL; Peters HA; Bontenbal M; Jänicke F; Klijn JG
    Cancer Res; 1992 Nov; 52(21):6101-5. PubMed ID: 1394237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.